Opus Genetics IRD Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's payments of stock issuance costs?
- Opus Genetics (IRD) reported payments of stock issuance costs of $98K in Q4 2025.
- How has Opus Genetics's payments of stock issuance costs changed year-over-year?
- Opus Genetics's payments of stock issuance costs increased by 113.0% year-over-year, from $46K to $98K.
- What is the long-term trend for Opus Genetics's payments of stock issuance costs?
- Over 4 years (2021 to 2025), Opus Genetics's payments of stock issuance costs has grown at a 11.1% compound annual growth rate (CAGR), from $1.51M to $2.3M.
- What does payments of stock issuance costs mean?
- Represents the cash outflows incurred to facilitate the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. These costs are directly attributable to capital-raising activities and reduce the net proceeds received from equity offerings.